Three years on from start-up, most of GlaxoSmithKline PLC's core R&D organizational entities, Discovery Performance Units, have survived their first review, conducted at the end of last year, and are headed, "in the right direction," according to GSK R&D Chairman Moncef Slaoui. But should all Big Pharma companies structure their research this way? And what exactly are the attributes, cultural or otherwise, that are considered central to the success of DPUs? (See Also see "GSK Says R&D Productivity Up, But Story Is About Culture, Not Numbers" - Pink Sheet, 20 February, 2012.).
GSK's DPUs, or "biotechs on steroids" as one company researcher puts it, fed 27 drug programs into GSK's late stage pipeline between 2008 and 2011, a figure spotlighted by Slaoui...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
